Update on pediatric vasculitis

Current Opinion in Pediatrics

Volumn 17, Issue 6, 2005, Pages 695-702

  Kim, Susan ^a   Dedeoglu, Fatma ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Henoch Schonlein purpura; Kawasaki Disease; Pediatric vasculitis; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PLACEBO; PREDNISONE; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; ATHEROSCLEROSIS; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC POLYMORPHISM; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; NEPHRITIS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PEDIATRICS; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

BACTERIAL INFECTIONS; CHILD; HUMANS; PROGNOSIS; TREATMENT OUTCOME; VASCULITIS; VIRUS DISEASES;

EID: 28044459817     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mop.0000187190.97166.83     Document Type: Review

References (82)

1. Gardner-Medwin JM, Dolezalova P, Cummins C, Southwood TR. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002; 360:1197-1202.
2. Yang YH, Hung CF, Hsu CR, et al. A nationwide survey on epidemiological characteristics of childhood Henoch-Schonlein purpura in Taiwan. Rheumatology (Oxford) 2005; 44:618-622. This retrospective study reviewed the epidemiology and characteristics of 2759 children with HSP in Taiwan between 1999 and 2002.
3. Dolezalova P, Telekesova P, Nemcova D, Hoza J. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J Rheumatol 2004; 31:2295-2299. This study reported on the incidence of childhood vasculitides in the Czech Republic from 1997 to 1999 on the basis of pediatrician questionnaires.
4. Mills JA, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Henoch-Schonlein purpura. Arthritis Rheum 1990; 33:1114-1121.
5. Chang WL, Yang YH, Wang LC, et al. Renal manifestations in Henoch Schonlein purpura: a 10-year clinical study. Pediatr Nephrol 2005; 20:1269-1272. This study retrospectively examined the renal manifestations in 261 children in Taiwan who experienced HSP between 1991 and 2001. The study showed a lower prevalence and better outcome of HSP nephritis in comparison with previous reports.
6. Chang WL, Yang YH, Lin YT, Chiang BL. Gastrointestinal manifestations in Henoch-Schonlein purpura: a review of 261 patients. Acta Paediatr 2004; 93:1427-1431. This study retrospectively examined the gastrointestinal manifestations in 261 children in Taiwan who experienced HSP between 1991 and 2001.
7. Misra AK, Biswas A, Das SK, et al. Henoch-Schonlein purpura with intracerebral haemorrhage. J Assoc Physicians India 2004; 52:833-834.
8. Narchi H. Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review. Arch Dis Child 2005; 90:916-920. The author reviewed and summarized 12 studies of 1133 children with HSP in eight different countries from 1981 to 1990 and reported that 97% of patients experienced renal involvement within 6 months of diagnosis.
9. Nussinovitch N, Elishkevitz K, Volovitz B, Nussinovitch M. Hypertension as a late sequela of Henoch-Schonlein purpura. Clin Pediatr 2005; 44:543-547. The authors retrospectively reviewed the charts of 155 children with HSP. Seven patients had hypertension at long-term follow-up, and two of these patients did not have any evidence of significant renal involvement on presentation. These data support the need for long-term regular blood pressure monitoring in all children with HSP.
10. Halling SF, Soderberg MP, Berg UB. Henoch Schonlein nephritis: clinical findings related to renal function and morphology. Pediatr Nephrol 2005; 20:46-51. The renal function of 73 patients and biopsy specimens from 40 of 73 children with HSP nephritis was reviewed. Patients with lower glomerular filtration rates and higher levels of proteinuria had more severe morphologic changes; however, patients with mild to moderate proteinuria were also found to have severe morphologic changes, which suggests the need for earlier biopsy in this group.
11. Hidaka H, Okada T, Matsumoto H, et al. Henoch-Schonlein purpura nephritis in a patient infected with the human immunodeficiency virus. Nippon Jinzo Gakkai Shi 2003; 45:387-392.
12. Cioc AM, Sedmak DD, Nuovo GJ, et al. Parvovirus B19 associated adult Henoch Schonlein purpura. J Cutan Pathol 2002; 29:602-607.
13. Mattoo TK, al-Mutair A, al-Khatib Y, et al. Group A beta-haemolytic streptococcal infection and Henoch-Schonlein purpura with cardiac, renal and neurological complications. Ann Trop Paediatr 1997; 17:381-386.
14. Ayoub EM, McBride J, Schmiederer M, Anderson B. Role of Bartonella henselae in the etiology of Henoch-Schonlein purpura. Pediatr Infect Dis J 2002; 21:28-31.
15. Kalman S, Ibrahim-Aydin H, Atay A. Henoch-Schonlein purpura in a child following varicella. J Trop Pediatr 2005; 51:240-241.
16. Robinson JL, Spady DW, Prasad E, et al. Bartonella seropositivity in children with Henoch-Schonlein purpura. BMC Infect Dis 2005; 5:21.
17. Bartunkova J, Tesar V, Sediva A. Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin Immunol 2003; 106:73-82.
18. Rovel-Guitera P, Diemert MC, Charuel JL, et al. IgA antineutrophil cytoplasmic antibodies in cutaneous vasculitis. Br J Dermatol 2000; 143:99-103.
19. Lin JJ, Stewart CL, Kaskel FJ, Fine RN. IgG and IgA classes of anti-neutrophil cytoplasmic autoantibodies in a 13-year-old girl with recurrent Henoch-Schonlein purpura. Pediatr Nephrol 1993; 7:143-146.
20. Kaneko K, Suzuki Y, Yabuta K. Absence of anti-neutrophil cytoplasmic antibody (ANCA) in Henoch-Schonlein purpura and immunoglobulin A nephropathy. Acta Paediatr Jpn 1994; 36:619-622.
21. Sinico RA, Tadros M, Radice A, et al. Lack of IgA antineutrophil cytoplasmic antibodies in Henoch-Schonlein purpura and IgA nephropathy. Clin Immunol Immunopathol 1994; 73:19-26.
22. Ozaltin F, Bakkaloglu A, Ozen S, et al. The significance of IgA class of anti-neutrophil cytoplasmic antibodies (ANCA) in childhood Henoch-Schonlein purpura. Clin Rheumatol 2004; 23:426-429. In this study, levels of immunoglobulin-G and immunoglobulin-A ANCA were studied in HSP patients and disease control individuals (13 patients with other vasculitides: PAN, acute urticarial vasculitis, unclassified vasculitis, hypocomplentemic vasculitis). Significantly, more HSP patients had immunoglobulin-A ANCA and lacked immunoglobulin-G ANCA during the acute phase of disease, which suggests that they may serve a role in the diagnosis of HSP.
23. Stefansson Thors V, Kolka R, Sigurdardottir SL, et al. Increased frequency of C4B*Q0 alleles in patients with Henoch-Schonlein purpura. Scand J Immunol 2005; 61:274-278. In Iceland, C4 null alleles were more commonly found in patients with HSP than in control individuals, which suggests that abnormalities in complement function pre-dispose patients to the development of HSP.
24. Motoyama O, Iitaka K. Henoch-Schonlein purpura with hypocomplementemia in children. Pediatr Int 2005; 47:39-42. Patients with HSP in Japan were found to have transient hypocomplementemia, which did not correlate with the severity of HSP.
25. Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005; 84:1-11.
26. Hatemi G, Masatlioglu S, Gogus F, Ozdogan H. Necrotizing vasculitis associated with familial Mediterranean fever. Am J Med 2004; 117:516-519.
27. Huber AM, King J, McLaine P, et al. A randomized, placebo-controlled trial of prednisone in early Henoch Schonlein Purpura. BMC Med 2004; 2:7. This prospective, randomized, double-blind, placebo-controlled study of the use of prednisone in HSP did not show any decrease in renal involvement or gastrointestinal complications at 1 year.
28. Tarshish P, Bernstein J, Edelmann CM Jr. Henoch-Schonlein purpura nephritis: course of disease and efficacy of cyclophosphamide. Pediatr Nephrol 2004; 19:51-56. This study reported on the disease course and efficacy of cyclophosphamide in HSP nephritis in a randomized controlled trial. No differences in outcome were found between the treatment and control groups: three patients in the treatment group and four in the control group experienced ESRD at last follow-up.
29. Flynn JT, Smoyer WE, Bunchman TE, et al. Treatment of Henoch-Schonlein purpura glomerulonephritis in children with high-dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 2001; 21:128-133.
30. Tanaka H, Suzuki K, Nakahata T, et al. Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr Nephrol 2003; 18:347-350.
31. Dajani AS, Taubert KA, Gerber MA, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993; 87:1776-1780.
32. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation 1996; 94:1379-1385.
33. Ayusawa M, Sonobe T, Uemura S, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005; 47:232-234.
34. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114:1708-1733. In addition to providing a comprehensive overview of Kawasaki Disease, this multidisciplinary group of experts provided guidelines for its diagnosis, treatment, and long-term management.
35. Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. J Infect Dis 2005; 191:499-502. A significant association between this coronavirus and Kawasaki Disease was found in this single-center retrospective study.
36. •].
37. •].
38. Minami T, Suzuki H, Takeuchi T, et al. A polymorphism in plasma platelet-activating factor acetylhydrolase is involved in resistance to immunoglobulin treatment in Kawasaki disease. J Pediatr 2005; 147:78-83. This group reported on an increased frequency of a polymorphism of PAFAH genes and significantly lower levels of PAFAH serum activity in patients with Kawasaki Disease resistant to IVIG therapy, suggesting that this enzymatic deficiency may contribute to IVIG resistance.
39. Burns JC, Shimizu C, Gonzalez E, et al. Genetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki disease. J Infect Dis 2005; 192:344-349. A striking inverse relation between CCR5 polymorphisms and the incidence of Kawasaki Disease in Asian countries compared with northern European countries is described.
40. Burns JC, Shimizu C, Shike H, et al. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun 2005. These researchers implicated interleukin-4 and susceptibility to Kawasaki Disease using a family-based candidate gene association study analysis.
41. Wu SF, Chang JS, Wan L, et al. Association of IL-1Ra gene polymorphism, but no association of IL-1beta and IL-4 gene polymorphisms, with Kawasaki disease. J Clin Lab Anal 2005; 19:99-102. These investigators reported an association of interleukin-1Ra gene polymorphism but not interleukin-4.
42. Onouchi Y, Onoue S, Tamari M, et al. CD40 ligand gene and Kawasaki disease. Eur J Hum Genet 2004; 12:1062-1068. CD40 ligand polymorphisms were implicated in the increased susceptibility to Kawasaki Disease and increased incidence of coronary artery lesions in a Japanese population.
43. Furuno K, Yuge T, Kusuhara K, et al. CD25+CD4+ regulatory T cells in patients with Kawasaki disease. J Pediatr 2004; 145:385-390. Regulatory T cells, which have been described to play a role in various inflammatory and autoimmune conditions, were described to be decreased during the acute phase of Kawasaki Disease and to return to normal after treatment.
44. Ye F, Foell D, Hirono KI, et al. Neutrophil-derived S100A12 is profoundly upregulated in the early stage of acute Kawasaki disease. Am J Cardiol 2004; 94:840-844. This study reported on the correlation between neutrophil-derived S100A12 (a protein with proinflammatory properties) and Kawasaki Disease and responsiveness to IVIG treatment.
45. Biezeveld MH, van Mierlo G, Lutter R, et al. Sustained activation of neutrophils in the course of Kawasaki disease: an association with matrix metalloproteinases. Clin Exp Immunol 2005; 141:183-188. This study reported prolonged neutrophil activation in patients with Kawasaki Disease, measured by levels of serum neutrophil elastase, for as long as 3 months after the onset of disease, despite normalization of CRP, suggesting more persistent neutrophil activation and inflammation than was previously suspected.
46. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
47. Mitani Y, Sawada H, Hayakawa H, et al. Elevated levels of high-sensitivity C-reactive protein and serum amyloid-A late after Kawasaki disease: association between inflammation and late coronary sequelae in Kawasaki disease. Circulation 2005; 111:38-43. Kawasaki Disease patients with persistent coronary artery lesions were found to have significantly elevated high-sensitivity CRP levels in comparison with patients with normal coronary arteries or regressed coronary artery lesions.
48. Cheung YF, Ho MH, Tam SC, Yung TC. Increased high sensitivity C reactive protein concentrations and increased arterial stiffness in children with a history of Kawasaki disease. Heart 2004; 90:1281-1285. Kawasaki Disease patients with and without coronary artery lesions were reported to have higher CRP levels as well as carotid artery stiffness, which implicated low-grade inflammation in the development of vessel disease.
49. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341-347.
50. Hsieh KS, Weng KP, Lin CC, et al. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Pediatrics 2004; 114:e689-e693. The authors treated 162 patients over 10 years with high-dose IVIG (2 g/kg) at diagnosis and low-dose aspirin 72 hours after the patients experienced defervescence. Treatment without high-dose aspirin in the acute stage of Kawasaki Disease seemed to have no impact on the IVIG response rate or the rate of aneurysm formation: approximately 5% of patients required a second dose of IVIG, and the incidence of coronary aneurysms was 4.14%, with a significantly higher incidence in the IVIG-resistant group (P = 0.033, 2.92% compared with 25%).
51. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005; 146:662-667. The successful treatment of Kawasaki Disease with infliximab is described.
52. Sundel RP, Baker AL, Fulton DR, Newburger JW. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial. J Pediatr 2003; 142:611-616.
53. Weiss JE, Eberhard BA, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31:808-810.
54. Levy DM, Silverman ED, Massicotte MP, et al. Longterm outcomes in patients with giant aneurysms secondary to Kawasaki disease. J Rheumatol 2005; 32:928-934. These researchers reported on 22 Kawasaki Disease patients with coronary aneurysms. Regardless of anticoagulation, regression of giant and nongiant aneurysms occurred, and there was no significant difference in ischemic events in either group.
55. Lightfoot RW Jr, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990; 33:1088-1093.
56. Ozen S, Besbas N, Saatci U, Bakkaloglu A. Diagnostic criteria for polyarteritis nodosa in childhood. J Pediatr 1992; 120:206-209.
57. Ozen S, Anton J, Arisoy N, et al. Juvenile polyarteritis: results of a multicenter survey of 110 children. J Pediatr 2004; 145:517-522. A multicenter survey of juvenile polyarteritis of 110 children from 21 centers in 2004 reported a mean overall age of 9 years (range 1-16 years), with an equal occurrence between sexes. In this study, 86.4% of patients presented with constitutional symptoms, 74.5% with skin lesions, 50.9% with fever, 17.3% with gastrointestinal symptoms, 11.8% with renal symptoms, 14.5% with nervous system symptoms, 14.5% with hypertension, and 85.7% with musculoskeletal features. During a median follow-up time of 48 months, remission was reported in 62.9% of patients, and persistent disease was reported in 23.6%, with one report of mortality and two reports of ESRD in this group, which suggested a better renal survival and lower relapse rates in comparison with adults.
58. Bourgeais AM, Dore MX, Croue A, et al. Cutaneous polyarteritis nodosa following hepatitis B vaccination. Ann Dermatol Venereol 2003; 130:205-207.
59. De Keyser F, Naeyaert JM, Hindryckx P, et al. Immune-mediated pathology following hepatitis B vaccination: two cases of polyarteritis nodosa and one case of pityriasis rosea-like drug eruption. Clin Exp Rheumatol 2000; 18:81-85.
60. Begier EM, Langford CA, Sneller MC, et al. Polyarteritis nodosa reports to the vaccine adverse event reporting system (VAERS): implications for assessment of suspected vaccine-provoked vasculitis. J Rheumatol 2004; 31:2181-2188. This report concluded that a clear causal link between vaccination and the development of PAN does not exist, on the basis of reports of current adverse events from 1990 to 2001.
61. Al-Bishri J, Riche NL, Pope JE. Refractory polyarteritis nodosa successfully treated with infliximab. J Rheumatol 2005; 32:1371-1373.
62. Calabrese LH, Mallek JA. Primary angiitis of the central nervous system: report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine 1988; 67:20-39.
63. Matsell DG, Keene DL, Jimenez C, Humphreys P. Isolated angiitis of the central nervous system in childhood. Can J Neurol Sci 1990; 17:151-154.
64. Yaari R, Anselm IA, Szer IS, et al. Childhood primary angiitis of the central nervous system: two biopsy-proven cases. J Pediatr 2004; 145:693-697.
65. Lanthier S, Lortie A, Michaud J, et al. Isolated angiitis of the CNS in children. Neurology 2001; 56:837-842.
66. Gallagher KT, Shaham B, Reiff A, et al. Primary angiitis of the central nervous system in children: 5 cases. J Rheumatol 2001; 28:616-623.
67. Benseler S, Schneider R. Central nervous system vasculitis in children. Curr Opin Rheumatol 2004; 16:43-50. This paper provides a comprehensive review of primary angiitis of the central nervous system in children.
68. Benseler SM, Deveber G, Hawkins C, et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis Rheum 2005; 52:2159-2167. This paper reported four children with normal angiography, elevated inflammatory markers, and abnormal magnetic resonance imaging studies who received diagnoses of confirmed primary small vessel CNS vasculitis based on brain biopsy. The authors describe this as a newly recognized entity, angiography-negative PACNS, emphasizing the importance of brain biopsy because small vessel disease cannot consistently be detected on angiography.
69. Numano F, Okawara M, Inomata H, Kobayashi Y. Takayasu's arteritis. Lancet 2000; 356:1023-1025.
70. Vanoli M, Daina E, Salvarani C, et al. Takayasu's arteritis: a study of 104 Italian patients. Arthritis Rheum 2005; 53:100-107.
71. Becker RW, Sohn RL, Poulik JM, Berguer R. Takayasu's arteritis presenting as uveitis in a 5-year-old girl. Ann Vasc Surg 2005; 19:258-262.
72. McDonald MA, Ojaimi E, Favilla I. Anterior uveitis in a child with Takayasu's arteritis. Clin Experiment Ophthalmol 2004; 32:336-339.
73. Liang P, Hoffman GS. Advances in the medical and surgical treatment of Takayasu arteritis. Curr Opin Rheumatol 2005; 17:16-24.
74. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-498.
75. Frosch M, Foell D. Wegener granulomatosis in childhood and adolescence. Eur J Pediatr 2004; 163:425-434. This is a nice review of Wegener's granulomatosis in childhood and adolescence. Lung involvement occurs in 74 to 87% of patients, kidney involvement in 53 to 100%, eye involvement in 48 to 53%, and upper airway involvement in as many as 91%. Approximately 15% of cases of Wegener's granulomatosis are initially diagnosed in patients younger than 19 years of age.
76. Heeringa P, Tervaert JW. Pathophysiology of ANCA-associated vasculitides: are ANCA really pathogenic? Kidney Int 2004; 65:1564-1567.
77. Aries PM, Hellmich B, Reinhold-Keller E, Gross WL. High-dose intravenous azathioprine pulse treatment in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2004; 43:1307-1308.
78. Benenson E, Fries JW, Heilig B, et al. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin Rheumatol 2005; 24:251-257.
79. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352:351-361.
80. Langford CA, Talar-Williams C, Barron KS, Sneller MC. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 2003; 114:463-469.
81. Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004; 51:278-283.
82. Keogh KA, Wylam ME, Stone JH, Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:262-268.